Innovaccer previews new provider AI copilot at HIMSS24

The latest stories trending on MedCity News.

Editor's Pick

Top Story Innovaccer Previews Its New Provider AI Copilot at HIMSS24 On Monday at HIMSS24, Innovaccer unveiled a preview of its new AI copilot for providers, which is slated to go on the market by the end of 2024. The solution is a portable tablet device designed to provide clinicians with point-of-care support — it flags care and coding gaps, assists with clinical documentation and advises clinicians on possible diagnosis pathways. Sponsored Content Improving Healthcare Access for High-Risk Patient Populations Presented by Verizon Business and MedCity News Gary Lynch, global practice lead, and CTO Insurance and Life Science at Verizon Business,  shared how it is improving healthcare access to high risk patient populations. He also shared how Verizon Business is working with UC Davis to improve health equity.

Featured News

UpLift Acquires Higher Ed Mental Health Company With its acquisition of TAO Connect, UpLift now serves over 170 enterprise customers in the U.S. and Canada. It covers four million people, including more than two million students at more than 120 higher education institutions. Debunked Episode 2(audio): Discussing Unfair Hospital Pricing & How CA is Overseeing Large Transactions Episode 2 of the Debunked (audio) show focuses on how hospitals are inflating prices for outpatient procedures and how California is looking at healthcare M&A and trying to address price increases and anti-competitive behavior. What Drives Specialty Medication Enrollment Conversions? It's Not What You Think. We can no longer simply worry about the enrollment form as the only hurdle in therapy initiation. We must view the entire patient journey as an interconnected set of challenges that need solving. And I believe achieving that goal is within reach. Let's Make This the Last World Obesity Care Week By eliminating the term "obesity" in favor of person-centric language, we pave the way for a more equitable healthcare system that prioritizes the well-being of all individuals, regardless of their size or shape. Boehringer Ingelheim Places €25M Bet on Sosei's Novel Approach to Schizophrenia Sosei Heptares' schizophrenia drug candidate addresses a novel, difficult-to-drug target for neurological disorders. Boehringer Ingelheim can exercise its option on the small molecule following a Phase 1 test expected to yield data in 2025.

Resources

MedCity Pivot Podcast: A Conversation with Lumen CEO Daniel Tal Mor In this episode of the MedCity Pivot Podcast, we looked deeper into Lumen, a consumer device meant to give people better understanding over how the body burns fat or carbs. We caught up with Daniel Tal Mor, CEO of Lumen, at Vive, and it was intriguing. What was the CEO of a direct-to-consumer company doing at an industry conference where the buyers were generally providers, employers and payers? Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe